Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib vs Standard of Care in Advanced Triple-Negative Breast Cancer
NCT00246571Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2006
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of sunitinib in triple-negative breast cancer (TNBC), sponsored by Pfizer. Started Jan 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00246571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246571.